WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 1-December 2016 (data as of 18-November-2016)
Next overall update June 2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 54'9601 Infant (under 12 months) mortality rate: 212
GDP / capita (US$): 55'8371 Child (under 5 years) mortality rate: 252

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 321'774  319'449  317'136  314'799  312'390  282'896  252'848  229'588 
Births 4'025  4'008  4'008  4'024  4'054  4'004  3'986  3'450 
Surviving infants 4'002  3'985  3'984  3'999  4'028  3'976  3'948  3'406 
Pop. less than 5 years 19'701  19'729  19'851  20'020  20'157  19'247  18'933  16'645 
Pop. less than 15 years 60'977  60'878  60'858  60'939  61'090  60'139  54'613  52'126 
Female 15-49 years 73'394  73'457  73'578  73'682  73'710  71'950  66'324  58'853 

Number of reported cases

(Click for retrospective incidence data for United States of America (the))
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  188  667  187  55  220  85  27'786  13'506 
Mumps
ChartChart
  1'308  1'223  584  229  386  323 
Pertussis
ChartChart
  20'679  32'971  28'639  48'277  18'719  7'867  4'570  1'730 
Polio*
ChartChart
 
Rubella
ChartChart
  176 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  30  25  26  37  37  35  64  95 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United States of America (the))
Vaccine year result method % card seen                                                
BCG         
DTP1          98  98  98  97  98  99* 
DTP3          95  95  94  94  96  94  96 
DTP4          84 
IPV1          97 
HepB_BD          72  72  74  72  69 
HepB3          92  92  91  90  91  90 
Hib3          93  93  93  93  94  93 
JapEnc         
MCV1          92  92  92  91  92  91  86 
MCV2         
PCV1          97  97 
PCV3          93  93  92  92  94 
Pol3          93  93  93  93  94  90  95 
Rota1          87  83 
RotaC          72  72  73  69  67 
RCV1          92  91 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United States of America (the))
DTP1
ChartChart
  97  97  97  96  97  99  96  98 
DTP3
ChartChart
  95  95  94  94  96  94  90  96 
HepB3
ChartChart
  92  92  91  90  91  90 
HepB_BD
ChartChart
  72  72  74  72  69 
Hib3
ChartChart
  93  93  93  93  94  93 
MCV1
ChartChart
  92  92  92  91  92  91  90  86 
MCV2
ChartChart
 
PCV3
ChartChart
  93  93  92  92  94 
Pol3
ChartChart
  93  93  93  93  94  90  85  95 
RCV1
ChartChart
  92  92  92  91  92  91  90  86 
RotaC
ChartChart
  72  72  73  69  67 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 2, 4, 6, >15 months; >4 years; Yes
DTaP 2, 4, 6, > 15 months; > 4 years; Yes
DTaPHepBIPV 2, 4, 6 months; Yes
DTaPHibIPV 2, 4, 6 months;
DTaPIPV > 4 years (x2);
HPV >11 years (x3 doses); Yes
HepA 12 months; >18 months; Yes
HepB_Adult 18 years; Yes Adults with certain medical conditions, behaviors, travel, or desire to decrease risk of Hepatitis B not vaccinated as a child
HepB_Pediatric 1st contact; +2, +6 months;
Hib 2, 4, 6, > 12 months; Yes
IPV 2, 4, > 6 months; > 4 years; Yes
Influenza_Adult Yes elderly, adults with chronic diseases, pregnant women, health care workers, and other risk groups
Influenza_Pediatric Yes and children with chronic diseases
MMR 12 months; 4 years; Yes
MenACWY >11, >16 years; Yes
Pneumo_conj 2, 4, 6, >12 months; Yes Also recommended for all adults 65Y and for younger adults with immune compromising conditions
Pneumo_ps 65 years; Yes Also recommended for 18-64Y with certain conditions
Rotavirus 2, 4, 6 months; Yes
Td Yes recommended every year
Tdap 11 years; Yes Also recommended for adult with no prior Tdap vaccination and for child 7yrs and older with incomplete pertussis vacciantion
Varicella >12 months; 4 years; Yes
Zoster 60 years; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No           
What years does the MYP cover? number       Yes       
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number              
Nº districts with DTP3 coverage >=80% number        
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number        
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes             
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes      Yes       

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes      Yes   

Sources

 1  "The 2016 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.